BPC-157 prescription,
coming soon.
BPC-157 is a 15-amino-acid gastric pentadecapeptide with the most extensive preclinical healing evidence of any peptide in the research literature. Physician-supervised prescriptions expected when FDA finalizes Category 1 reclassification.
Be notified the day prescriptions open. No spam.
Why BPC-157 is the most sought-after healing peptide.
Derived from a naturally occurring protein in human gastric juice, BPC-157 has demonstrated tissue repair across virtually every tissue type tested in preclinical research — earning it the nickname "the wolverine peptide" in the peptide therapy community.
Multi-tissue healing
Unlike peptides that target a single tissue type, BPC-157 has demonstrated repair activity across muscle, tendon, ligament, bone, nerve, gut lining, and vascular tissue in published preclinical studies. No other peptide in the research literature shows this breadth.
Oral bioavailability
BPC-157 is one of the rare peptides that survives gastric degradation and maintains activity when taken orally — a direct consequence of its origin as a gastric juice fragment. This makes it uniquely versatile compared to injection-only peptides.
Extensive research base
Over 100 published studies from the University of Zagreb under Professor Predrag Sikirić spanning three decades. The preclinical evidence base for BPC-157 is larger than most peptides that have entered clinical trials.
Two administration routes, different strengths.
BPC-157 is one of the only therapeutic peptides with demonstrated activity via both injection and oral administration. The choice depends on what you're treating.
| Feature | Subcutaneous injection | Oral (capsule/liquid) |
|---|---|---|
| Best for | Localized injuries — tendons, ligaments, joints, muscle tears | Gut healing, systemic inflammation, IBS, leaky gut, ulcers |
| Bioavailability | High — near-complete at injection site | Moderate — survives gastric acid due to gastric origin |
| Onset | Faster localized tissue response (days to weeks) | Slower systemic effects (weeks to months) |
| Prescription needed | Pending Category 1 | Pending Category 1 |
| Self-administration | Requires reconstitution and subcutaneous injection technique | Simple capsule or sublingual liquid |
| Typical dose | 250–500 mcg 1–2x daily near injury site | 250–500 mcg 1–2x daily on empty stomach |
Everything about BPC-157 prescription.
BPC-157 injection protocol
Reconstitution, dosage, injection sites, subcutaneous technique, and cycle length for injectable BPC-157.
02 / 06Benefits and research
Tissue repair mechanisms, the Sikirić research program, gut healing, tendon recovery, and neuroprotection.
03 / 06Side effects and safety
Safety profile, reported adverse effects, the human trial gap, and what the preclinical data shows.
04 / 06Cost and pricing
Compounding pharmacy pricing, oral vs injectable cost comparison, and what to budget monthly.
05 / 06Before and after
Realistic healing timelines for tendons, gut, joints, and muscle injuries from BPC-157 therapy.
06 / 06Prescription FAQ
Regulatory timeline, Category 1 vs FDA approval, telehealth access, and the TB-500 stack question.
Don't miss the window.
BPC-157 will be the most in-demand peptide the day prescriptions open. Join the waitlist now.